Posted by Michael Wonder on 15 Jan 2025
FDA approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
15 January 2025 - In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year.
Eli Lilly announced today that the US FDA has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.
